Introduction
============

Breast cancer patients with tumors that are estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive have lower risks of mortality after their diagnosis compared to women with ER- and/or PR-negative disease \[[@B1]-[@B6]\]. Clinical trials have also shown that the survival advantage for women with hormone receptor-positive tumors is enhanced by treatment with adjuvant hormonal and/or chemotherapeutic regimens \[[@B7]-[@B9]\]. However, few studies have evaluated variations in the risks of breast cancer-specific mortality across ER/PR status by either demographic or clinical characteristics. The goal of this study was to determine whether the greater relative risk of breast cancer mortality observed among women with hormone receptor-negative tumors was similar for those with different demographic characteristics, such as race/ethnicity, age of cancer diagnosis, and year of cancer diagnosis, and for those with different tumor characteristics, such as stage, grade, tumor size, and histology, using data from Surveillance, Epidemiology, and End Results (SEER), the population-based tumor registry program of the National Cancer Institute (NCI). Such an assessment may further elucidate the relationships between various prognostic indicators in breast cancer and provide knowledge regarding the prognostic utility of ER/PR status by demographic and clinical tumor characteristics.

Materials and methods
=====================

Patient selection
-----------------

The cohort for this study was assembled using data from the NCI\'s SEER program in the United States \[[@B10]\]. Since the early 1970s, the SEER program has collected incidence and survival data from population-based cancer registries spanning five states and four metropolitan areas: Connecticut, Hawaii, Iowa, New Mexico, Utah, San Francisco-Oakland (CA), Detroit (MI), Seattle (Puget Sound) (WA), and Atlanta (GA). In 1992, two population-based registries were added: San Jose-Monterey (CA) and Los Angeles (CA). SEER began collecting data on ER and PR status in 1990 for breast cancer cases. Therefore, only data from 1 January 1990 through 31 December 2001 were included in this analysis.

We identified 209,276 women at least 30 years old with a primary diagnosis of invasive carcinoma of the breast as potentially eligible subjects for this study. Women under the age of 30 years were excluded because the occurrence of breast cancer among this age group is rare. Also excluded were 1,873 women whose breast carcinomas were diagnosed only by autopsy or death certificate or whose diagnostic confirmation of breast cancer was unknown. Because our primary analysis focused on associations between joint ER/PR status and breast cancer-specific mortality, we excluded 50,291 women missing tumor marker data for ER and/or PR (24% of the total potentially eligible subjects). After the noted exclusions, 155,175 subjects were included in the study.

Women were categorized into four groups according to their joint ER/PR status: ER+/PR+, ER+/PR-, ER-/PR+, and ER-/PR-. The SEER registries provide information on age of diagnosis, year of diagnosis, and race/ethnicity. Data on other clinical characteristics, such as tumor histology, grade, stage (American Joint Committee on Cancer \[AJCC\] classification system), and size, were also available. Additionally, SEER collects data regarding the first course of cancer-directed surgical and radiation treatment interventions. However, SEER does not make data on adjuvant chemotherapy or hormonal therapy publicly available. SEER does not collect information on other relevant factors such as reproductive history, anthropometrics, medical history, family history of cancer, or cancer screening history.

Outcome measures
----------------

Each SEER registry routinely updates vital status and follow-up information for all patients with cancer. Survival time is calculated in months by using the subject\'s date of breast cancer diagnosis and one of the following: (a) date of death, (b) date last known to be alive, or (c) the most recent follow-up cutoff date. The follow-up cutoff date for the SEER data used in our analysis was 31 December 2001. Because we were interested primarily in cause-specific mortality, our outcome of interest was death due to breast cancer as indicated by cause-of-death International Classification of Diseases codes. Women who died of causes other than breast cancer were censored at their date of death.

Statistical analysis
--------------------

The statistical software program Stata for Macintosh version 9.1 (StataCorp LP, College Station, TX, USA) was used to perform all analyses. Women with ER+/PR+ tumors served as the referent category in all analyses because this was the largest ER/PR subgroup. Associations between joint ER/PR receptor status and breast cancer mortality risk within categories of diagnosis age (\<50, 50 to 64, ≥65 years), diagnosis year (3-year intervals: 1990 to 1992, 1993 to 1995, 1996 to 1998, and 1999 to 2001), race/ethnicity (non-Hispanic white, terminology used is base on the SEER registries descriptions. If you would prefer to change, OK. African-American, Native American, Asian/Pacific Islander, Hispanic white), histologic tumor type (ductal, lobular, ductal/lobular, inflammatory, mucinous, tubular, comedo, medullary, papillary), AJCC stage grouping (I, II, III, IV), SEER grade (I, well differentiated; II, moderately differentiated; III, poorly differentiated; IV, undifferentiated), size (0 to 1.9, 2 to 5, \>5 cm), and axillary lymph node status (binary -- yes/no or 0, 1 to 3, 4 to 10, \>11 positive) were estimated using the Cox proportional hazards model. Unknown factors or those with missing data were excluded from all model estimates. We used likelihood ratio testing to evaluate whether variations in mortality risks by these categories were statistically significant. Hazard ratios (HRs) and their associated 95% confidence intervals (CIs) were calculated as estimates of relative risks of mortality \[[@B11],[@B12]\]. Based on log-log survival curves, proportional hazards assumption in these data was validated for all categories of ER/PR status except for ER-PR+. This is likely a consequence of ER-/PR+ being the rarest ER/PR subtype, and for this subgroup, a gross violation of the proportional hazards assumption was not observed. In our analyses, we evaluated age of diagnosis, year of diagnosis, SEER registry site (stratified variable), race/ethnicity, histologic type, tumor size, stage, grade, and lymph node status as potential confounders in multivariate Cox regression modeling. We also evaluated the possible influence of initial cancer treatments (surgery/radiation -- yes/no) given that treatment recommendations are based on tumor characteristics and that therapeutic interventions are associated with survival. We assessed whether associations between ER/PR status and demographic/clinical characteristics were different for varying levels of a factor by fitting interaction models. For each model, dummy variables were created and each represented the combination of an ER/PR category and the characteristic assessed, with ER+PR+ and the following characteristics as referent categories: age less than 50 years, year of diagnosis 1990 to 1992, non-Hispanic white, tumor grade 1, tumor stage 1, tumor size less than 2 cm, negative lymph nodes, and ductal tumor histology. Each full model with the cross-categorized variables was compared to the reduced model (main effects only) by likelihood ratio testing to assess statistical significance. We also estimated trends in HRs for each ER/PR profile and the following: (a) age at diagnosis, per 5 years (30 to \<35 years referent), (b) diagnosis year, per year (1990 referent), (c) tumor stage (stage 1 referent), (d) tumor size (0 to \<1 cm \[referent\], 1 to \<2, 3 to \<4, 4 to \<5, 5 to \<10, ≥10), (e) axillary nodal positivity (0 \[referent\], 1 to 3, 4 to 10, ≥11), and (f) tumor grade (grade 1 referent). These variables were treated as continuous variables for trend estimates. All statistical tests were two-sided, and *p*values of 0.05 or less were considered significant.

Results
=======

Within the identified cohort of 155,175 women with known joint ER/PR receptor status, 98,463 cases had ER+/PR+ tumors (63%). Of the remaining women, 19,886 cases had ER+/PR- tumors (13%), 4,896 cases had ER-/PR+ tumors (3%), and 31,930 cases had ER-/PR- tumors (21%). Older women were more likely to be diagnosed with ER+/PR+ tumors, whereas more than one third of women 30 to 39 years old presented with ER-/PR- tumors (Table [1](#T1){ref-type="table"}). The proportion of tumors that were ER+/PR+ increased over the study period, whereas the proportions of tumors that were ER+/PR- and ER-/PR- held fairly constant, and the proportion of tumors that were ER-/PR+ declined. In general, for the other characteristics shown in Table [1](#T1){ref-type="table"}, ER+/PR+ and ER+/PR- tumors were similar to each other and ER-/PR+ and ER-/PR- tumors were similar to each other. Specifically, compared to women with ER+PR+ and ER+/PR- tumors, those diagnosed with ER-/PR+ and ER-/PR- tumors were somewhat more likely to be younger and African-American, to have larger tumors, more advanced disease stage, and higher tumor grade, and to present with axillary lymph node metastases. In addition, women with ER-/PR+ and ER-/PR- tumors were somewhat less likely to have lobular, ductal/lobular, mucinous, or tubular carcinomas and were somewhat more likely to have inflammatory, comedo, or medullary carcinomas.

The risks of breast cancer-specific mortality were elevated among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors relative to women with ER+/PR+ tumors across all subcategories of age at cancer diagnosis (Table [2](#T2){ref-type="table"}). Age was an effect modifier of the relationship between ER/PR status and relative risk of breast cancer mortality (*p*= 0.03). Specifically, HRs for ER-/PR+ and ER-/PR- disease were particularly high among women 65 years of age and older. For each 5-year increase in age, a 5% to 7% elevation in mortality risk was observed within each ER/PR profile (*p*for trend \< 0.0001, all profiles) (Table [3](#T3){ref-type="table"}). Among the population of women with ER-/PR- tumors relative to women with ER+/PR+ tumors, a higher relative mortality risk was associated with a tumor diagnosed in the most recent years versus a tumor diagnosed in the early 1990s (*p*for interaction \< 0.0001). However, decreases in HRs ranging from 4% to 8% per year were observed with increasing calendar year within each ER/PR profile and the magnitude of this reduction was greater among women with ER+ disease than ER- disease. In general, the magnitudes of the HRs associated with each ER/PR profile were comparable across race/ethnicity classifications (*p*for interaction = 0.77).

Elevations in breast cancer mortality risks were observed among women with ER+/PR-, ER-/PR+, and ER-/PR- tumors relative to women with ER+/PR+ tumors across the majority of clinical characteristics examined (Table [2](#T2){ref-type="table"}). The magnitudes of these relative risks did not vary appreciably by stage; also, for each increase in tumor stage level, two-fold or greater increases in mortality risks were observed within each ER/PR profile (*p*for trend \< 0.0001) (Table [3](#T3){ref-type="table"}). Tumor size, lymph node status, histology, and grade appeared to modify the relationship between ER/PR status and relative risk of mortality. For tumor size and grade, the mortality risks associated with ER-/PR+ tumors were particularly high among women whose tumors were either more than 5 cm in size or of high grade. The mortality risks associated with ER-/PR- tumors, relative to ER+/PR+ tumors, were particularly high among women whose tumors were less than 2 cm in size or of low grade (Table [2](#T2){ref-type="table"}). In addition, the HRs increased with increasing tumor size, number of axillary lymph node metastases, and disease grade within each ER/PR profile (*p*for trend \< 0.0001, all profiles) (Table [3](#T3){ref-type="table"}). The magnitude of the associated relative mortality risk depended on ER/PR status. For example, women with ER-/PR- tumors had a 24% increase in the relative risk of breast cancer mortality with each increase in tumor grade level, whereas women with ER+/PR+ tumors had a 62% elevated mortality risk with each increase in tumor grade level. With respect to histology, compared to women with ER+/PR+ tumors, women with ER+/PR- tumors had elevated risks of mortality if their tumor was ductal or lobular, women with ER-/PR+ tumors had elevated risks of mortality if their tumor was ductal or inflammatory, and women with ER-/PR- tumors had elevated risks of mortality across all histologies, except for medullary carcinoma. Due to the sparse number of subjects in each hormonal category and limited or no recorded deaths, data were not shown for mucinous, papillary, and tubular carcinomas.

Discussion
==========

Previous studies have shown survival advantages among women with hormone receptor-positive tumors relative to women with hormone receptor-negative tumors \[[@B6],[@B9],[@B13]-[@B16]\]. A recent study by Grann and coworkers \[[@B17]\] that also used data collected from the SEER program reported that joint ER/PR status was an independent predictor of outcome in a large cohort of women with breast carcinoma. Our study expands on this study, further evaluating the association between ER/PR status and breast cancer-specific mortality within subgroups of women defined by personal characteristics (including race/ethnicity, age at cancer diagnosis, and year of cancer diagnosis) and tumor characteristics (including histology, stage, grade, size, and axillary lymph node metastases). In general, we observed that the higher relative risks of mortality associated with having an ER+/PR-, an ER-/PR+, or an ER-/PR- tumor relative to an ER+/PR+ tumor were consistently present across almost all tumor characteristics. Even among women with poor prognoses, such as those with stage IV disease, multiple positive lymph nodes, or tumors of high grade, differences in the relative risk of mortality by ER/PR status were observed. We also estimated mortality trends by ER/PR status within the study population. Within each ER/PR profile, we document an increase in the relative risk of breast cancer mortality for each 5-year increase in age and for each incremental increase in tumor stage, size, grade, or axillary lymph node metastases. These findings are in agreement with the known correlation between increased breast cancer mortality risk and increasing tumor stage, size, grade, or regional lymph node metastases \[[@B18],[@B19]\]. We observed a decreased mortality trend each year over the study period of 1990 to 2001 which was greatest in magnitude among women with ER+ tumors. This trend may be related to improvements in breast cancer treatments and/or early detection methods resulting in improved patient outcomes.

We did observe some variations in the association between ER/PR status and risk of breast cancer mortality by tumor size, grade, and histology. Relative to ER+/PR+ patients, and within subcategories of tumor size and grade, the highest observed relative mortality risks were among ER-/PR- patients whose tumors were small (0 to 1.9 cm) or of low grade (grade 1 and 2). These elevated risks are likely related to adjuvant treatment standards given that hormonal therapy generally is recommended for women with ER+/PR+ disease, regardless of tumor size. Conversely, adjuvant chemotherapy is not routinely recommended for ER-/PR- patients whose tumors are small and have favorable features (that is, negative lymph nodes, highly differentiated) \[[@B20]\]. Our data also showed that ER-/PR+ patients whose tumors were more than 5 cm in size or of high grade had particularly elevated relative mortality risks (HRs = 2.2 and 2.1, respectively) that were higher than those with ER+/PR- tumors of similar size and grade (HRs = 1.3 and 1.4, respectively), suggesting that ER negativity may have a greater influence on mortality risk than PR negativity among women with these tumor types. Compared to women with ER+/PR+ tumors, those with ER-/PR- tumors had increased risks of mortality across almost all histologic classifications, suggesting that combined ER/PR negativity has implications for relative mortality risk, regardless of tumor histology. The one noted exception was that ER/PR status did not appear to be related to the relative risk of mortality among women with medullary carcinomas. Medullary carcinomas are rare, and although they are typically high-grade, they tend to have well-defined, distinct borders. Their prognosis is more favorable than that of other invasive breast carcinomas, such as ductal carcinoma \[[@B21]\].

Researchers who examined the risk of invasive breast carcinoma diagnosis among women of different races reported that certain ethnicities have elevated risks of presenting with ER-/PR- tumors. African-Americans, Asians, Native Americans, and Hispanic whites were found to have greater risks of presenting with ER-/PR- breast tumors compared to non-Hispanic whites \[[@B22]-[@B25]\]. Although it has been shown that women of certain racial/ethnic groups have increased risks of developing hormone receptor-negative tumors, our results show little or no difference in mortality risks within ethnic classes for each ER/PR profile. For example, African-American women whose tumors were ER-/PR+ or ER-/PR- were found to have relative risks of breast cancer mortality similar to non-Hispanic whites with ER-/PR+ or ER-/PR- tumors, respectively.

There are potential study limitations using SEER data. First, ER/PR status, tumor histology, and tumor grade were not assessed centrally since the data recorded by SEER are derived from review of clinical pathology reports. Most importantly, assays and techniques used for ER/PR testing likely varied both across and within laboratories over the course of this study. For example, cutoff points may have been dissimilar in differentiating hormone receptor positivity. High cutoff values may result in tumors being misclassified as ER- \[[@B26]\]. However, assay techniques for ER and PR have improved since their inception nearly 30 years ago and receptor status can be appropriately determined with relative ease \[[@B27],[@B28]\]. In the period to which this study was restricted (1990 to 2001), pathology laboratories in general routinely performed ER/PR testing of breast cancer. Also reassuring is the fact that the proportions of the four joint tumor ER/PR receptor profiles in our study population were comparable to those reported in other studies \[[@B13],[@B14]\].

The exclusion of subjects with no recorded ER/PR data is a second potential limitation of this study. The absence of recorded hormone receptor data has been reported to be associated with age and year of diagnosis, tumor stage, grade, histology, and SEER registries \[[@B17],[@B29]\], and thus the lack of ER/PR data on these cases could bias our results. However, the number of SEER records missing ER/PR data has declined over time and the decline has been shown to be consistent across all age categories \[[@B29]\]. The proportion of records containing ER/PR data for this cohort increased over time, ranging from 67.5% in 1990 to 73% in the years 1994 to 1995 and 80.7% in 2001, results that are consistent with prior reports \[[@B17]\].

Survivorship for SEER registries is tracked through state vital records and the National Death Index (NDI) established by the National Center for Health Statistics (NCHS). Cause-of-death data in relation to death certificate completion or coding are subject to misclassification. However, US death certificates are checked at several levels for completeness before transmission to the NCHS. The NDI is reported to have the highest sensitivity of all major US mortality databases \[[@B30]\]. In addition, a study that evaluated the accuracy of the cause-of-death code found small discrepancy rates (ranging from 4% to 7%) between NDI Plus codes, final study codes, and NCHS nosologists\' original codes \[[@B31]\].

The SEER program does not collect data regarding mammography screening program participation within the designated state and metropolitan tumor registries. Mammography screening programs have been shown to improve patient outcomes \[[@B32]\]. The decreased mortality trend we observed each year over the study period, particularly among women with ER+ tumors, may be due in part to screening programs.

A final limitation of this study is that SEER registries do not provide data on the receipt of adjuvant or hormonal therapies following primary surgical and/or radiotherapy interventions. Treating hormone receptor-positive tumors with hormonal therapies has been shown to be a contributing factor in better survival among women with breast cancer \[[@B9]\]. A large proportion of the survival advantage experienced by ER+/PR+ patients compared to ER-/PR- patients may be due to the use of hormonal therapy. Our data indicate that in 1990 to 1992, when the use of hormonal therapy had just begun, ER-/PR- patients had a 1.7-fold greater relative risk of mortality; however, by 1999 to 2001, when hormonal therapy was widely integrated into clinical practice and guidelines for its use were well established, women with ER-/PR- tumors had a 4.9-fold greater relative risk of mortality. In future years, the advent of better chemotherapy treatments for the ER- patient population may result in improved disease-free survival and overall survival. Recent studies have reported that the large survival differences among ER+ patients treated with hormonal therapy versus ER- patients treated with chemotherapy have dwindled and that ER- patients are now deriving a greater benefit from improved chemotherapy regimens with risk reductions as high as 49% \[[@B33],[@B34]\].

Conclusion
==========

Overall, our findings suggest that the higher risks of mortality in women with ER+/PR-, ER-/PR+, and ER-/PR- tumors, compared to women with ER+/PR+ tumors, are largely independent of the various demographic and clinical tumor characteristics assessed in this study. This indicates that the prognostic utility of ER/PR status is for the most part independent of these other factors. However, the strength of the associations we assessed did vary within subcategories of certain factors. The higher relative mortality risks we identified among ER-/PR- patients with small or low-grade tumors raise the question of whether there may be a beneficial role for adjuvant chemotherapy in this population. The lack of data on adjuvant chemotherapies from SEER limits our ability to make this determination. Other underlying biological factors may account for the observed variations in tumor hormone receptor status and mortality risk, requiring additional research to be conducted.
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Selected characteristics among breast cancer cases by hormone receptor status: SEER program, 1990--2001

                               ER+PR+   ER+PR-   ER-PR+   ER-PR-                                                      
  ---------------------------- -------- -------- -------- -------- ------ ------ ------- ------ ----- -------- ------ ------
  Age at diagnosis, years                                                                                             
   30--39                      4,903    5.0      49.5     885      4.5    8.9    569     11.6   5.7   3,558    11.1   35.9
   40--49                      18,575   18.9     60.9     2,490    12.5   8.2    1,508   30.8   4.9   7,929    24.8   26.0
   50--59                      21,807   22.1     61.4     4,464    22.5   12.5   1,161   23.7   3.3   8,094    25.4   22.8
   60--69                      22,019   22.4     65.9     4,752    23.9   14.2   801     16.4   2.4   5,856    18.3   17.5
   70--79                      20,667   21.0     68.2     4,662    23.4   15.4   584     11.9   1.9   4,401    13.8   14.5
   ≥80                         10,492   10.6     67.7     2,633    13.2   17.0   273     5.6    1.8   2,092    6.6    13.5
  Diagnosis year                                                                                                      
   1990--1992                  16,500   16.8     61.6     3,751    18.9   14.0   1,111   22.7   4.1   5,435    17.0   20.3
   1993--1995                  22,087   22.4     61.7     4,514    22.7   12.6   1,485   30.3   4.1   7,728    24.2   21.6
   1996--1998                  27,734   28.2     64.2     5,239    26.3   12.1   1,367   27.9   3.2   8,884    27.8   20.5
   1999--2001                  32,142   32.6     65.2     6,382    32.1   12.9   933     19.1   1.9   9,883    31.0   20.0
  SEER registry                                                                                                       
   Atlanta, GA                 5,696    5.8      59.4     1,171    5.9    12.2   381     7.8    4     2,344    7.3    24.4
   Connecticut                 11,093   11.3     61.4     2,448    12.3   13.6   602     12.3   3.3   3,914    12.3   21.7
   Detroit, MI                 10,559   10.7     60.4     2,314    11.6   13.2   539     11     3.1   4,063    12.7   23.3
   Hawaii                      4,149    4.2      67.0     703      3.5    11.3   273     5.6    4.4   1,072    3.4    17.3
   Iowa                        10,238   10.4     65.2     1,914    9.6    12.2   530     10.8   3.4   3,017    9.4    19.2
   Los Angeles, CA             15,586   15.8     61.4     3,399    17.1   13.4   919     18.8   3.6   5,491    17.2   21.6
   New Mexico                  4,066    4.1      61.8     885      4.5    13.5   193     3.9    2.9   1,435    4.5    21.8
   San Francisco-Oakland, CA   13,063   13.3     63.9     2,750    13.8   13.5   652     13.3   3.2   3,957    12.4   19.4
   San Jose, CA                5,474    5.5      65.3     1,134    5.7    13.5   228     4.7    2.7   1,548    4.9    18.5
   Seattle, WA                 14,241   14.5     68       2,517    12.7   12.0   423     8.6    2.0   3,770    11.8   18.0
   Utah                        4,298    4.4      66.9     651      3.3    10.1   156     3.2    2.5   1,319    4.1    20.5
  Race                                                                                                                
   Non-Hispanic white          78,805   81.7     65.4     15,716   80.5   13.0   3,515   73.5   2.9   22,532   72.1   18.7
   African-American            5,724    5.9      48.0     1,488    7.6    12.5   504     10.5   4.2   4,206    13.5   35.3
   Native American             284      0.3      55.0     57       0.3    11.0   23      0.5    4.5   152      0.5    29.5
   Asian/Pacific Islander      6,065    6.3      65.1     1,061    5.4    11.4   382     8.0    4.1   1,805    5.8    19.4
   Hispanic white              5,585    5.8      57.8     1,203    6.2    12.4   359     7.5    3.7   2,524    8.1    26.1
   Other/Unknown               2,000    \-       \-       361      \-     \-     113     \-     \-    711      \-     \-
  Tumor histology                                                                                                     
   Ductal                      71,199   72.3     62.7     13,981   70.3   12.3   3,641   74.4   3.2   24,722   77.4   21.8
   Lobular                     8,980    9.1      73.6     2,160    10.9   17.7   283     5.8    2.3   784      2.5    6.4
   Ductal/Lobular              7,576    7.7      76.7     1,341    6.7    13.6   233     4.8    2.4   722      2.3    7.3
   Inflammatory                543      0.5      37.8     191      1.0    13.3   90      1.8    6.3   611      1.9    42.6
   Mucinous                    2,927    3.0      80.9     486      2.4    13.5   41      0.8    1.1   164      0.5    4.5
   Tubular                     1,696    1.7      79       327      1.6    15.2   44      0.9    2.1   79       0.3    3.7
   Comedo                      1,159    1.2      43.6     318      1.6    12.0   179     3.6    6.7   1,003    3.1    37.7
   Medullary                   266      0.3      14.7     148      0.8    8.2    97      2.0    5.4   1,292    4.0    71.7
   Papillary                   582      0.6      79.0     58       0.3    7.9    10      0.2    1.3   87       0.3    11.8
   Other                       3,535    3.6      49.4     876      4.4    12.2   278     5.7    3.9   2,466    7.7    34.5
  Tumor stage                                                                                                         
   I                           50,172   52.4     69.2     9,232    48     12.7   1,999   42.7   2.8   11,114   36.2   15.3
   II                          37,335   39.0     60.3     7,606    39.5   12.3   2,068   44.2   3.3   14,878   48.4   24.1
   III                         5,332    5.5      51.3     1,471    7.6    14.1   385     8.2    3.7   3,210    10.4   30.9
   IV                          2,943    3.1      52.1     936      4.9    16.6   230     4.9    4.1   1,536    5.0    27.2
   Unstaged                    2,681    \-       \-       641      \-     \-     214     \-     \-    1,192    \-     \-
  Tumor grade                                                                                                         
   1                           18,012   21.8     81.1     2,885    17.5   13.0   405     9.9    1.8   914      3.3    4.1
   2                           40,642   49.3     74.2     7,133    43.4   13.0   1,324   32.5   2.4   5,682    20.6   10.4
   3                           22,082   26.8     44.4     6,027    36.6   12.1   2,174   53.3   4.4   19,412   70.4   39.1
   4                           1,774    2.1      45.0     413      2.5    10.5   173     4.3    4.4   1,579    5.7    40.1
   Unknown                     15,953   \-                3,428    \-            820     \-           4,343    \-     
  Tumor size (cm)                                                                                                     
   0--1.9                      56,547   59.9     69.2     10,302   54.6   12.6   2,271   49.5   2.8   12,576   41.8   15.4
   2--5                        32,977   34.9     58.7     7,135    37.8   12.7   1,891   41.3   3.4   14,147   47.1   25.2
   \>5                         4,949    5.2      48.8     1,432    7.6    14.1   422     9.2    4.2   3,330    11.1   32.9
   Unknown                     3,990    \-       \-       1,017    \-     \-     312     \-     \-    1,877    \-     \-
  Axillary lymph node status                                                                                          
   Negative                    54,948   65.3     64.8     10,428   63.0   12.3   2,622   61.0   3.1   16,749   60.3   19.8
   Positive                    29,234   34.7     60.9     6,110    37.0   12.7   1,675   39.0   3.5   11,015   39.7   22.9
   Unknown                     14,281   \-       \-       3,348    \-     \-     599     \-     \-    4,166    \-     \-
  Surgical treatment                                                                                                  
   Performed                   96,387   98.0     63.7     19,216   96.7   12.7   4,764   97.4   3.2   30,847   96.8   20.4
   Not performed               2,012    2.0      52.7     648      3.3    17.0   126     2.6    3.3   1,032    3.2    27
   Unknown                     64       \-       \-       22       \-     \-     6       \-     \-    51       \-     \-
  Radiation therapy                                                                                                   
   Treated                     46,859   48.5     65.5     8,694    44.5   12.1   2,048   42.9   2.9   13,922   44.8   19.5
   None                        49,776   51.5     61.9     10,836   55.5   13.4   2,725   57.1   3.4   17,131   55.2   21.3
   Unknown                     1,828    \-       \-       356      \-     \-     123     \-     \-    877      \-     \-

ER, estrogen receptor; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.

###### 

Breast cancer mortality risk by hormone receptor status among women of different diagnosis age, race/ethnicity, diagnosis year, tumor stage, grade, histology, and axillary lymph node positivity^a^

                                  ER+/PR+   ER+/PR-   ER-/PR+   ER-/PR-                                                                                                      
  ------------------------------- --------- --------- --------- --------- ------- ----- ------------- ------- ----- ----- ------------- -------- ------- ----- ------------- ---------
  All cases^b^                    98,463    7,319     1.0       19,886    2,434   1.4   1.3--1.5^c^   4,896   848   1.8   1.6--1.9^c^   31,930   6,300   2.3   2.2--2.4^c^   
  Age at diagnosis, years^d^                                                                                                                                                 
   \<50                           16,962    1,042     1.0       2,387     245     1.2   1.1--1.4^c^   1,430   209   1.6   1.4--1.9^c^   8,056    1,323   2.1   1.9--2.3^c^   
   50--64                         23,467    1,104     1.0       4,745     416     1.5   1.3--1.7^c^   1,072   124   1.5   1.2--1.8^c^   7,651    1,214   2.3   2.1--2.5^c^   
   ≥65                            25,078    1,496     1.0       5,563     540     1.5   1.3--1.7^c^   718     119   2.1   1.8--2.6^c^   5,536    1,020   2.6   2.4--2.8^c^   0.03
  Diagnosis year^e^                                                                                                                                                          
   1990--1992                     8,298     1,285     1.0       1,889     419     1.3   1.2--1.5^c^   597     146   1.6   1.3--1.9^c^   2,850    831     1.7   1.5--1.9^c^   
   1993--1995                     13,665    1,348     1.0       2,688     428     1.5   1.3--1.7^c^   944     160   1.5   1.2--1.8^c^   4,859    1,234   2.2   2.0--2.4^c^   
   1996--1998                     19,350    837       1.0       3,493     282     1.5   1.3--1.7^c^   971     121   2.1   1.7--2.6^c^   6,181    1,059   2.8   2.5--3.1^c^   
   1999--2001                     24,194    172       1.0       4,625     69      1.6   1.2--2.1^c^   708     25    3.6   2.3--5.1^c^   7,353    433     4.9   4.1--6.0^c^   \<0.001
  Race/Ethnicity^f^                                                                                                                                                          
   Non-Hispanic white             53,397    2,831     1.0       10,187    916     1.5   1.3--1.6^c^   2,396   313   1.8   1.6--2.0^c^   15,371   2,462   2.3   2.2--2.5^c^   
   African-American               3,536     348       1.0       907       125     1.2   1.0--1.5^c^   293     60    1.7   1.3--2.2^c^   2,734    615     2.2   1.9--2.6^c^   
   Native American                196       19        1.0       34        11      1.5   0.5--3.8      12      1     1.7   0.1--16.4     102      25      3.4   1.5--7.3^c^   
   Asian/Pacific Islander         4,497     189       1.0       748       63      1.8   1.3--2.4^c^   267     34    1.6   1.1--2.4^c^   1,273    166     2.3   1.8--2.8^c^   
   Hispanic white                 3,881     255       1.0       819       83      1.3   1.0--1.7^c^   252     44    1.9   1.3--2.6^c^   1,763    289     2.3   1.9--2.8^c^   0.77
  Tumor stage^g^                                                                                                                                                             
   I                              33,821    487       1.0       6,038     146     1.4   1.2--1.7^c^   1,369   51    1.6   1.2--2.1^c^   7,704    391     2.3   2.0--2.7^c^   
   II                             27,363    2,110     1.0       5,472     674     1.4   1.3--1.6^c^   1,529   248   1.6   1.4--1.9^c^   11,051   2,069   2.3   2.2--2.5^c^   
   III                            3,410     659       1.0       922       252     1.3   1.2--1.6^c^   245     104   2.1   1.7--2.6^c^   1,940    763     2.3   2.0--2.6^c^   
   IV                             672       302       1.0       192       102     1.3   1.0--1.6^c^   59      42    1.9   1.3--2.7^c^   357      245     2.3   1.9--2.8^c^   0.45
  Tumor size (cm)^h^                                                                                                                                                         
   0--1.9                         39,418    865       1.0       6,957     243     1.4   1.2--1.6^c^   1,607   91    1.5   1.2--1.9^c^   8,799    715     2.6   2.3--2.9^c^   
   2--5                           22,579    2,081     1.0       4,781     708     1.5   1.3--1.6^c^   1,331   253   1.8   1.5--2.0^c^   10,214   2,019   2.2   2.1--2.4^c^   
   \>5                            2,718     526       1.0       761       206     1.3   1.1--1.6^c^   217     89    2.2   1.7--2.7^c^   1,730    636     2.2   1.9--2.5^c^   \<0.001
  Axillary lymph node status^i^                                                                                                                                              
   Negative                       42,451    942       1.0       7,924     324     1.6   1.4--1.8^c^   1,898   114   2.0   1.6--2.4^c^   12,541   1,006   2.8   2.6--3.1^c^   
   1--3                           14,953    1,021     1.0       2,828     324     1.5   1.3--1.7^c^   790     133   1.8   1.5--2.1^c^   4,857    977     2.5   2.3--2.7^c^   
   4--10                          5,313     861       1.0       1,133     277     1.4   1.2--1.6^c^   332     108   1.7   1.3--2.1^c^   2,268    793     2.4   2.2--2.7^c^   
   ≥11                            2,549     734       1.0       739       249     1.2   1.0--1.4^c^   182     90    1.7   1.3--2.1^c^   1,386    692     2.2   1.9--2.4^c^   0.08
  Tumor histology^j^                                                                                                                                                         
   Ductal                         52,178    2,919     1.0       9,978     994     1.5   1.4--1.6^c^   2,711   390   1.8   1.6--2.0^c^   18,542   3,040   2.3   2.2--2.5^c^   
   Lobular                        3,975     186       1.0       938       64      1.4   1.0--1.9^c^   123     3     0.4   0.1--1.4      325      47      1.9   1.4--2.7^c^   
   Ductal/Lobular                 5,472     254       1.0       929       59      1.3   0.9--1.7      148     13    1.1   0.6--2.0      511      83      2.7   2.1--3.5^c^   
   Inflammatory                   241       52        1.0       77        22      1.4   0.8--2.3      39      19    3.4   1.9--6.1^c^   258      123     3.5   2.4--5.0^c^   
   Comedo                         652       91        1.0       187       19      0.6   0.4--1.1      91      16    1.2   0.7--2.1      556      109     1.6   1.2--2.1^c^   
   Medullary                      120       14        1.0       73        6       0.7   0.2--2.2      48      4     0.9   0.2--3.0      716      54      0.7   0.4--1.4      \<0.001
  Tumor grade^k^                                                                                                                                                             
   1                              13,854    156       1.0       2,141     40      1.6   1.1--2.3^c^   310     6     1.0   0.4--2.5      661      32      2.6   1.7--3.9^c^   
   2                              32,661    1,349     1.0       5,555     374     1.5   1.3--2.1^c^   1,074   95    1.7   1.3--2.1^c^   4,312    575     3.1   2.8--3.4^c^   
   3                              17,352    1,873     1.0       4,613     710     1.3   1.2--1.5^c^   1,694   319   1.7   1.5--1.9^c^   14,967   2,635   2.1   1.9--2.2^c^   
   4                              1,399     180       1.0       315       50      1.4   1.0--2.0^c^   124     25    2.1   1.4--3.3^c^   1,112    226     2.3   1.8--2.8^c^   \<0.001

^a^The reference ER/PR profile for all analyses was ER+/PR+. ^b^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^c^*p*\< 0.05. ^d^HRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^e^HRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^f^HRs adjusted for age and year at diagnosis, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). Race unknown, *n*= 3,185. ^g^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Stage unknown, *n*= 4,728. ^h^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status (categorical), and surgical and radiation treatment. Size unknown, *n*= 7,196. ^i^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, *n*= 22,394. ^j^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor grade, stage, lymph node status (categorical), and surgical and radiation treatment. Other/unknown histology, *n*= 7,155. ^k^HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status (categorical), and surgical and radiation treatment. Grade unknown, *n*= 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.

###### 

Trends in hazard ratios for breast cancer mortality associated with hormone receptor status and different demographic and clinical characteristics

                                     ER+/PR+   ER+/PR-      ER-/PR+   ER-/PR-                                 
  ---------------------------------- --------- ------------ --------- ------------ ------ ------------ ------ ------------
  Age at diagnosis, per 5 years^a^   1.05      1.04--1.06   1.07      1.04--1.09   1.07   1.03--1.10   1.06   1.05--1.07
  Diagnosis year, per year^b^        0.93      0.92--0.94   0.92      0.90--0.94   0.95   0.91--0.98   0.96   0.95--0.97
  Tumor stage^c^                     2.33      2.20--2.46   2.29      2.09--2.51   2.55   2.19--2.96   2.06   1.94--2.18
  Tumor size (cm)^d^                 1.27      1.24--1.30   1.29      1.24--1.34   1.33   1.25--1.41   1.22   1.20--1.25
  Axillary lymph node status^e^      1.71      1.65--1.78   1.55      1.46--1.66   1.61   1.44--1.80   1.64   1.58--1.70
  Tumor grade^f^                     1.62      1.55--1.70   1.49      1.36--1.63   1.72   1.46--2.03   1.24   1.16--1.32

^a^Five-year categories. Reference = 30 to \<35 years. HRs adjusted for year at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^b^Reference = 1990. HRs adjusted for age at diagnosis, race, SEER registry, tumor histology, grade, stage, surgical and radiation treatment, and lymph node status (positive/negative). ^c^Reference = stage 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Stage unknown, *n*= 4,728. ^d^Categories = 0 to \<1, 1 to \<2, 2 to \<3, 3 to \<4, 4 to \<5, 5 to \<10, ≥10 cm. Reference = 0 to \<1 cm. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, grade, lymph node status, and surgical and radiation treatment. Size unknown, *n*= 7,196. ^e^Categories = 0, 1 to 3, 4 to 10, ≥11. Reference = 0. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, grade, and surgical and radiation treatment. Nodal status unknown, *n*= 22,394. ^f^Reference = grade 1. HRs adjusted for age and year at diagnosis, race, SEER registry, tumor histology, stage, lymph node status, and surgical and radiation treatment. Grade unknown, *n*= 24,544. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
